GlobeNewswire Inc | Sep 14, 2020 08:30AM EDT

September 14, 2020

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that Fabian Tenenbaum, Chief Executive Officer, will present at two investor conferences in September: H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Fitzgerald Virtual Global Healthcare Conference.

H.C. Wainwright 22nd Annual Global Investment Conference

Date: Monday, September 14, 2020Time: 5:00 PM ET

Cantor Fitzgerald Virtual Global Healthcare Conference

Date: Thursday, September 17, 2020Time: 2:40 PM ET

A live audio webcast and replay of the presentations will be available in the Investors section on the Companys website at www.bellerophon.com.

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com.

Contacts At W2O Group: At LifeSci Advisors:Julie Normart Brian Ritchie(559) 974-3245 (212) 915-2578jnormart@w2ogroup.com britchie@lifesciadvisors.com